Skip to content

A comparative study on the effectiveness of Electroconvulsive therapy and ketamine in person suffering from depressive disorder not responding to medications

a comparative study on the effectiveness of electroconvulsive therapy and ketamine in person suffering from treatment resistant depressive disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027340
Enrollment
60
Registered
2020-08-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic features Health Condition 2: null- treatment resistant depression

Interventions

Intervention1: Electroconvulsive therapy(ECT): ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Pa

Sponsors

Ahana hospitals LLP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age range 18-60 years 2.Male and Female 3.Written informed consent. 4.Presence of Major Depressive Disorder as per DSM V guidelines 5.Refractory to at least two anti-depressant medications

Exclusion criteria

Exclusion criteria: 1. Co-morbid psychiatric diagnoses such as psychosis, bipolar disorder, substance dependence (including nicotine dependence) 2. Mental retardation, neurological disorders and severe medical illness 3. pregnancy or breast feeding 4.Diagnosis of major depressive disorder with psychotic features during the current depressive episode 5.allergy to ketamine

Design outcomes

Primary

MeasureTime frame
Patient reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 2-3 weeks ] Response is defined as at least a 50% improvement in Baseline QIDS-SR-16 score at End of Treatment Visit. The End of Treatment Visit will occur 3-5 weeks after the Baseline Visit. Timepoint: baseline and 2-3 weeks

Secondary

MeasureTime frame
clinician reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks ] Number of patients with an improvement in their Baseline MADRS score at the End of Treatment Visit. The End of Treatment Visit will occur 2-3 weeks after the Baseline Visit. Timepoint: baseline and 2-3 weeks

Countries

India

Contacts

Public ContactVikhram Ramasubramanian

Ahana hospitals

vikhram@ahanahospitals.in9443772233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026